Primary Tumor Location and Initial Diagnosis
Bob Marley's melanoma originated under the nail of his right big toe, a site consistent with acral lentiginous melanoma, the most common subtype in people with darker skin tones. The lesion was first noticed in 1977 after an injury during a soccer match in Paris, and a biopsy later confirmed malignant melanoma per American Cancer Society guidelines on skin cancer types.
The initial diagnosis was acral lentiginous melanoma, which differs from the more common sun-exposed melanomas and often appears on the palms, soles, or under nails. This subtype is not linked to UV exposure and is more frequent in people of African, Asian, or Hispanic descent, which aligns with Marley's background per Mayo Clinic's overview of acral melanoma risk factors.
Progression, Metastasis, and Spread of the Disease
By the time of definitive treatment, the melanoma had metastasized to Marley's lungs and brain, indicating stage IV disease. The spread was confirmed after he refused amputation of the toe for religious reasons and instead underwent a less radical excision followed by immunotherapy per NCCN clinical practice guidelines for melanoma staging.
Metastatic melanoma in the lungs often presents with coughing, shortness of breath, and chest pain, while brain metastases can cause headaches, seizures, and neurological deficits. Marley's rapid decline in 1980, including a collapse during a concert in Pittsburgh, reflected widespread central nervous system involvement per WHO fact sheet on cancer incidence and outcomes.
Treatment Timeline and Final Outcome
Marley's treatment included surgical excision of the primary toe lesion, radiation therapy for brain metastases, and the experimental immunotherapy agent Laetrile, which was not approved by the FDA and lacked robust clinical evidence per FDA policy on unapproved cancer treatments.
He died on May 11, 1981, in Miami, Florida, at age 36, from complications of metastatic melanoma. His case remains a widely cited example in dermatology and public health discussions about delayed diagnosis and cultural barriers to aggressive cancer care per CDC melanoma incidence and mortality data.